News

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug…
Read More...

Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in…
Read More...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+)…
Read More...

Bristol Myers Squibb and 2seventy bio, Inc. have announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel; ide-cel) for the…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with…
Read More...

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases,…
Read More...

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that the U.S. Food and Drug Administration (FDA)…
Read More...

Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal…
Read More...

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly…
Read More...

Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301. Xilio…
Read More...

Eisai Co., Ltd. announced that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and…
Read More...

Johnson & Johnsonannounced that the U.S. Food and Drug Administration (FDA) has approved EDURANT PED (rilpivirine) for the treatment of HIV-1 in combination with other…
Read More...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced it has signed an agreement to acquire the Genentech large-scale biologics…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and…
Read More...

Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved SPEVIGO (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP)…
Read More...

Bristol Myers Squibb announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased…
Read More...

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).…
Read More...

Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the U.S. Food and…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI (ciltacabtagene autoleucel, cilta-cel) for…
Read More...